Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Effective therapeutic interventions and clinical care of adults infected with HIV-1 require an understanding of factors that influence time of response to antiretroviral therapy. We have studied a cohort of 118 HIV-1-infected subjects naive to antiretroviral therapy and have correlated the time of response to treatment with a series of virological and immunological measures, including levels of viral load in blood and lymph node, percent of CD4 T cells in lymph nodes, and CD4 T-cell count in blood at study entry. Suppression of viremia below the limit of detection, 50 HIV-1 RNA copies/mL of plasma, served as a benchmark for a successful virological response. We employed these correlations to predict the length of treatment required to attain a virological response in each patient. Baseline plasma viremia emerged as the factor most tightly correlated with the duration of treatment required, allowing us to estimate the required time as a function of this one measure.
Rizzardi
G P
GP
Laboratory of AIDS Immunopathogenesis, Department of Internal Medicine, Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland.
De Boer
R J
RJ
Hoover
S
S
Tambussi
G
G
Chapuis
A
A
Halkic
N
N
Bart
P A
PA
Miller
V
V
Staszewski
S
S
Notermans
D W
DW
Perrin
L
L
Fox
C H
CH
Lange
J M
JM
Lazzarin
A
A
Pantaleo
G
G
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D002219:Carbamates; D015331:Cohort Studies; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008198:Lymph Nodes / Q000821:virology; D019888:Nelfinavir / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D019258:Saquinavir / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018119:Stavudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy*; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D054303:HIV Reverse Transcriptase; D019259:Lamivudine; D019888:Nelfinavir; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019258:Saquinavir; D018119:Stavudine; D013449:Sulfonamides; D015215:Zidovudine; D000099227:Abacavir; C095108:amprenavir